全文获取类型
收费全文 | 13046篇 |
免费 | 1263篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 875篇 |
妇产科学 | 41篇 |
基础医学 | 1845篇 |
口腔科学 | 184篇 |
临床医学 | 811篇 |
内科学 | 1229篇 |
皮肤病学 | 199篇 |
神经病学 | 572篇 |
特种医学 | 89篇 |
外国民族医学 | 1篇 |
外科学 | 214篇 |
综合类 | 835篇 |
一般理论 | 1篇 |
预防医学 | 5380篇 |
眼科学 | 36篇 |
药学 | 1509篇 |
6篇 | |
中国医学 | 407篇 |
肿瘤学 | 176篇 |
出版年
2024年 | 30篇 |
2023年 | 234篇 |
2022年 | 714篇 |
2021年 | 1137篇 |
2020年 | 616篇 |
2019年 | 606篇 |
2018年 | 522篇 |
2017年 | 493篇 |
2016年 | 490篇 |
2015年 | 547篇 |
2014年 | 763篇 |
2013年 | 1098篇 |
2012年 | 620篇 |
2011年 | 703篇 |
2010年 | 534篇 |
2009年 | 493篇 |
2008年 | 499篇 |
2007年 | 511篇 |
2006年 | 400篇 |
2005年 | 336篇 |
2004年 | 319篇 |
2003年 | 272篇 |
2002年 | 246篇 |
2001年 | 220篇 |
2000年 | 158篇 |
1999年 | 149篇 |
1998年 | 140篇 |
1997年 | 112篇 |
1996年 | 133篇 |
1995年 | 125篇 |
1994年 | 121篇 |
1993年 | 91篇 |
1992年 | 107篇 |
1991年 | 91篇 |
1990年 | 94篇 |
1989年 | 67篇 |
1988年 | 96篇 |
1987年 | 76篇 |
1986年 | 78篇 |
1985年 | 74篇 |
1984年 | 72篇 |
1983年 | 34篇 |
1982年 | 45篇 |
1981年 | 29篇 |
1980年 | 27篇 |
1979年 | 24篇 |
1978年 | 28篇 |
1977年 | 13篇 |
1976年 | 17篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
61.
62.
Reviewing the definition of "elderly" 总被引:1,自引:0,他引:1
Hajime Orimo Hideki Ito Takao Suzuki Atsushi Araki Takayuki Hosoi Motoji Sawabe 《Geriatrics & Gerontology International》2006,6(3):149-158
Conventionally, "elderly" has been defined as a chronological age of 65 years old or older, while those from 65 through 74 years old are referred to as "early elderly" and those over 75 years old as "late elderly." However, the evidence on which this definition is based is unknown. We have attempted to review the definition of elderly by analyzing data from long-term longitudinal epidemiological studies, and clinical and pathological studies that have been accumulated at the Tokyo Metropolitan Geriatric Hospital and the Tokyo Metropolitan Institute of Gerontology. Our recommendation might be a starting point in developing a strategy for a successful society by reviewing the definition of elderly based on comprehensive evidence in all aspects of social, cultural and medical sciences. 相似文献
63.
L. Marzio F. Di Felice V. Celiberti O. Pieramico L. Grossi M. DiGioacchino B. P. Imbimbo F. Cuccurullo 《European journal of clinical pharmacology》1990,39(4):369-372
Summary To evaluate the influence of the stomach and the cholinergic system on gallbladder contraction induced by physiological stimuli, the reduction in gallbladder volume in 7 healthy volunteers has been studied by real-time ultrasonography after the oral and intraduodenal administration of olive oil, preceded by pretreatment with cimetropium bromide or placebo. After an overnight fast, each subject swallowed 50 ml olive oil or it was administered through a naso-duodenal tube in the proximal duodenum. Cimetropium bromide 5 mg or placebo was given intravenously under double-blind control.After the placebo pretreatment, gallbladder contraction was greater and faster after intraduodenal oil than after oral oil. Cimetropium bromide decreased the extent, velocity and duration of gallbladder contraction induced by intraduodenal olive oil but it only reduced the velocity of the contraction induced by oil given orally.It is concluded that in normal human subjects the stomach modulates the extent and velocity of postprandial gallbladder contraction and that anticholinergic agents antagonize the gastric and duodenal phases of the response of the gallbladder to a meal. 相似文献
64.
65.
M. Sibille N. Deigat V. Olagnier D. Vital Durand R. Levrat 《European journal of clinical pharmacology》1992,42(4):389-393
Summary All the clinical, laboratory and electrocardiographic adverse events detected during 24 Phase I studies in the same unit over a 5 y period are reported here. 430 healthy male volunteers were involved, corresponding to 5488 days of follow-up.The overall incidence of adverse events was 13.5%, with a significant difference between active drug (15.3%) and placebo (7.4%) treatments. There were 69 distinct types of adverse events. Headache was the most frequent symptom (2%). There were severe adverse events in 20 cases (0.36%), with an incidence of 20/430 per subject (4.6%). There were no deaths or life-threatening events.Although the main objective of Phase I studies is to determine the maximum dose tolerated, cause-effect relationships with adverse events are hard to establish, because of the frequency of adverse events with placebo, and because of the limited number of subjects included such studies. 相似文献
66.
We have studied 21 babies with IgE-mediated food allergy (FA) sensitized via breast milk. The diagnosis of IgE-mediated FA was based on the response to elimination diet and challenge tests, and was confirmed by positive RAST and skin tests. The children exhibited immediate symptoms, such as urticaria, angioedema, and asthma. Only 5/21 children developed tolerance to the offending food at the median age of 14 years. The children who failed to develop tolerance still have high levels of IgE antibodies towards the offending food. In conclusion, the results of our long-term follow-up study show that the natural history of FA in children sensitized via breast milk may be less optimistic than generally reported. 相似文献
67.
68.
The dietary intake and urinary output of iodine and the thyroid activity was measured in 12 living food eaters (people consuming uncooked, Lactobacilli rich vegan food) and omnivores. Seven day food record was used for calculating the dietary iodine intake, instrumental neutron activation analysis for measuring the urinary iodine output and RIA for determining of the thyroid hormones (TSH and FT4). The living food eaters were divided into two groups according to urinary iodine output: high iodine group (≥900 ug/d) and low iodine group (<200 ug/d). Thyroid activity in both groups was with in normal range. Dietary intake of iodine was dependent on the the use of seaweed. The highest amounts of dietary iodine observed in the present study, as assessed by the the urinary iodine output, can be harmful for susceptible subjects. On the other hand the calculated intake of iodine by living food eaters didn't fill the RDA. As an conclusion on a living food diet one has to ensure the sufficient intake of iodine by consuming seaweed or Kelp tablets daily. However the intake of these preparations needs to be kept at reasonble limits due to their possible high iodine content. More information of the iodine content of different seaweeds and seaweed products is needed. 相似文献
69.
E. Andrs G. Kaltenbach E. Noel M. Noblet‐Dick A.‐E. Perrin T. Vogel J.‐L. Schlienger M. Berthel J. F. Blickl 《International journal of laboratory hematology》2003,25(3):161-166
Background: It has been suggested that oral cobalamin (vitamin B12) therapy may be an effective therapy for treating cobalamin deficiencies related to food‐cobalamin malabsorption. However, the duration of this treatment was not determined. Patients and method: In an open‐label, nonplacebo study, we studied 30 patients with established cobalamin deficiency related to food‐cobalamin malabsorption, who received between 250 and 1000 μg of oral crystalline cyanocobalamin per day for at least 1 month. Endpoints: Blood counts, serum cobalamin and homocysteine levels were determined at baseline and during the first month of treatment. Results: During the first month of treatment, 87% of the patients normalized their serum cobalamin levels; 100% increased their serum cobalamin levels (mean increase, +167 pg/dl; P < 0.001 compared with baseline); 100% had evidence of medullary regeneration; 100% corrected their initial macrocytosis; and 54% corrected their anemia. All patients had increased hemoglobin levels (mean increase, +0.6 g/dl) and reticulocyte counts (mean increase, +35 × 106/l) and decreased erythrocyte cell volume (mean decrease, 3 fl; all P < 0.05). Conclusion: Our findings suggest that crystalline cyanocobalamin, 250–1000 μg /day, given orally for 1 month, may be an effective treatment for cobalamin deficiencies not related to pernicious anemia. 相似文献
70.
P. A. Thürmann C. Sonnenburg-Chatzopoulos R. Lissner 《European journal of clinical pharmacology》1995,49(3):237-242
In two independent trials 10 and 12 healthy volunteers received the novel intravenous immunoglobulin (IVIG) preparations BT 511 and BT 507, respectively. BT 511 contains 5 g human plasma proteins per 100 ml, more than 95% of which are immunoglobulins of the G class (IgG). BT 507 contains in addition 61 IU antibody against hepatitis B surface antigen (anti-HBs)·ml–1. In trial I volunteers received 4.0 ml/kg (n+4) and 8.0 ml·kg–1 (n+6) BT 511 to study the tolerability and the magnitude of the increase in immunoglobulins in plasma as well as their decline over 1 month. After administration of the lower dose, plasma IgG increased from 10.7 to 14.7 g·l–1 directly after the infusion. Following the 8.0 ml·kg–1 dose a more pronounced increase from 12.4 to 21.2 g·l–1 was observed. No adverse events occurred. After 1 month IgG concentrations had almost reached baseline values at 12.2 g·l–1 in the 4.0 ml·kg–1 group, but were still significantly increased at 15.2 g·l–1 after the high dose. There was a linear correlation between the maximal IgG plasma concentration and the subsequent decline of IgG during the 29-day observation period. After administration of BT 507 maximal anti-HBs concentrations of 1778 mU·ml–1 occurred 1.4 h after termination of the infusion. The terminal elimination half-life was 22.4 days, and total clearance and volume of distribution were determined to be 0.122 ml·min–1 and 5.41, respectively. The pharmacokinetic parameters calculated for anti-HBs as an indicator of IgG were in accordance with the pharmacokinetic behaviour of native IgG. 相似文献